Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) EBIT: 2022-2025

Historic EBIT for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$2.3 million.

  • bioAffinity Technologies' EBIT fell 16.16% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 24.35%. This contributed to the annual value of -$9.0 million for FY2024, which is 12.29% down from last year.
  • As of Q3 2025, bioAffinity Technologies' EBIT stood at -$2.3 million, which was up 8.85% from -$2.5 million recorded in Q2 2025.
  • bioAffinity Technologies' EBIT's 5-year high stood at -$684,119 during Q2 2022, with a 5-year trough of -$2.9 million in Q4 2024.
  • Its 3-year average for EBIT is -$2.2 million, with a median of -$2.3 million in 2025.
  • As far as peak fluctuations go, bioAffinity Technologies' EBIT slumped by 159.95% in 2023, and later increased by 13.97% in 2024.
  • Over the past 4 years, bioAffinity Technologies' EBIT (Quarterly) stood at -$1.6 million in 2022, then crashed by 44.26% to -$2.3 million in 2023, then fell by 25.79% to -$2.9 million in 2024, then fell by 16.16% to -$2.3 million in 2025.
  • Its EBIT was -$2.3 million in Q3 2025, compared to -$2.5 million in Q2 2025 and -$2.6 million in Q1 2025.